Masseter Botulinum Toxin vs. Buccal Fat Removal: Two Lower-Face Slimming Procedures That Are Not Interchangeable

Search interest in lower-face slimming has surged over the past five years, and two procedures dominate the conversation: masseter botulinum toxin injections and buccal fat pad removal. Because both are sold under the same vague promise, a slimmer or more contoured lower face, patients often assume they are alternatives to one another. Mechanistically, they are not. One shrinks a muscle. The other removes a fat compartment. Understanding that distinction is the single most important step in choosing correctly, or in choosing neither.

What masseter injections actually do. The masseter is a thick chewing muscle that runs along the angle of the jaw. In some people, particularly those who clench or grind their teeth, the muscle hypertrophies, meaning it enlarges with use the way any exercised muscle does. Botulinum toxin blocks the release of acetylcholine at the neuromuscular junction, which temporarily weakens the muscle. With reduced workload, the muscle atrophies over roughly six to twelve weeks, and the width of the lower face at the jaw angle decreases. The effect is reversible: as nerve terminals recover over three to six months, the muscle regains bulk unless treatment is repeated. Clinicians typically confirm masseter hypertrophy first by asking the patient to clench while palpating the jaw. If the fullness does not firm up on clenching, the volume is probably not muscle, and toxin will not meaningfully change it.

What buccal fat removal actually does. The buccal fat pad sits deeper in the midcheek, beneath the cheekbone and lateral to the corner of the mouth, cushioning the space between chewing muscles. Removal is a surgical procedure, usually performed through a small incision inside the mouth, in which a portion of the pad is excised. The result is a hollowing of the lower midcheek, which can accentuate the shadow beneath the cheekbone. Critically, this is permanent removal of structural fat, and the buccal pad naturally shrinks with age in many people. A face that looks pleasantly sculpted at 28 after buccal fat removal can look gaunt at 45, because the surrounding fat compartments also deflate over time. This delayed effect is the main reason many facial plastic surgeons describe the procedure as suitable for a narrow subset of patients with genuinely full, round midcheeks that persist at a stable, healthy weight.

Different tissues, different outcomes. Because the masseter sits at the jaw angle and the buccal pad sits in the midcheek, the two procedures change different regions of the face. Masseter reduction narrows the lower face when viewed from the front, softening a square jaw. Buccal fat removal hollows the area below the cheekbone, creating a more angular midface. A patient bothered by jaw width will see little benefit from buccal surgery, and a patient bothered by round cheeks will see little benefit from toxin. When patients report disappointment with either procedure, mismatched anatomy and expectation is a common thread.

Risk profiles are not comparable. Masseter toxin carries the general risks of injectable neuromodulators: bruising, asymmetry, temporary chewing fatigue, and, if the product diffuses into the risorius or zygomaticus muscles, a temporarily altered smile. These effects resolve as the toxin wears off. Buccal fat removal carries surgical risks, including injury to the parotid duct, which crosses the operative field, and injury to buccal branches of the facial nerve. Overresection cannot be undone without fat grafting, which is its own procedure with its own variability.

Cost and maintenance work in opposite directions. Toxin is lower cost per session but requires maintenance roughly two to four times per year to hold the result, though many patients find intervals lengthen over time as the muscle deconditions. Surgery is a higher single expense with no maintenance, but also no exit. Reversibility is a genuine clinical advantage of the injectable route for anyone uncertain how a slimmer lower face will suit them.

Who is a reasonable candidate for which. In broad strokes, clinicians tend to favor masseter toxin for patients with palpable masseter hypertrophy, a square lower face, or bruxism symptoms such as jaw tension and morning headaches, since the functional benefit and the aesthetic one overlap. Buccal fat removal is generally reserved for adults with disproportionately full midcheeks at a stable weight, ideally with fuller-than-average facial fat overall, and after a candid conversation about how the face thins with age. Patients whose facial fullness fluctuates with weight are usually poor candidates for surgery, because weight change will alter the result.

The bottom line. These procedures answer different anatomical questions. The useful first step is not choosing a procedure but identifying the tissue responsible for the fullness: muscle, fat, bone, or skin laxity. A clinician who examines the face at rest, during clenching, and in animation can usually tell within minutes. If a consultation jumps straight to a treatment plan without that assessment, that is a reasonable signal to seek a second opinion.